stockrowFate Therapeutics, Inc.
FATEFate Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.6 million, down 51.2% from fiscal 2024.
- Revenue
- +9.18%
- EPS
- +13.8%
- Free cash flow
- +8.96%
Quarter to June 2026, against a year earlier
Follow FATE
Alert me
Fate Therapeutics, Inc. (FATE) Return on invested capital
Fate Therapeutics, Inc.'s return on invested capital over the twelve months to 30 June 2026 was 0.00%, up 2617.4 percentage points from fiscal 2025 (−2,617.4%). Over the past ten years it has ranged from −2,617.4% (fiscal 2025) to 0.00% (fiscal 2020) — the current reading is the lowest in ten years. That is in line with the Biotechnology industry median of 0.00% and in line with the Healthcare sector median of 0.00%.
Return on invested capital, annual
Embed this chart
Annual newest first
| Period | Return on invested capital | Change (points) |
|---|---|---|
| FY2025 | −2,617.4% | (2,285.99) |
| FY2024 | −331.4% | (107.75) |
| FY2023 | −223.6% | 180.33 |
| FY2022 | −404.0% | (188.45) |
| FY2021 | −215.5% | (215.52) |
| FY2020 | 0.00% | 269.85 |
| FY2019 | −269.9% | (269.85) |
| FY2018 | 0.00% | 0.00 |
| FY2017 | 0.00% | 0.00 |
| FY2016 | 0.00% | 0.00 |
Against its own ten years
Return on invested capital against peers
| Company | Return on invested capital |
|---|---|
| KRRO Korro Bio, Inc. compare | 0.00% |
| ABEO Abeona Therapeutics Inc. compare | 0.00% |
| CABA Cabaletta Bio, Inc. compare | 0.00% |
| FATE Fate Therapeutics, Inc. | 0.00% |
| GLSI Greenwich LifeSciences, Inc. compare | 0.00% |
| ACIU AC Immune compare | 0.00% |
| EVMN Evommune Inc. compare | −82.5% |
| VNDA Vanda Pharmaceuticals Inc. compare | −180.2% |
| IMRX Immuneering Corporation compare | −198.4% |
| Biotechnology industry median | 0.00% |
| Healthcare sector median | 0.00% |
| Market median | 0.00% |
What Return on invested capital is
Return on Invested Capital shows how much after-tax operating profit a company earns on the money its lenders and shareholders have put in.
TTM: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) (latest quarter) + Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter) − Cash & Short Term Investments (latest quarter)); Annual: (Operating Income × 0.625) ÷ (Shareholders Equity (Total) + Long Term Debt (Total) + Current Part of Debt − Cash & Short Term Investments)